Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy.
作者信息
Filippatos Theodosios D, Elisaf Moses S
机构信息
Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
出版信息
J Thorac Dis. 2017 Aug;9(8):2308-2310. doi: 10.21037/jtd.2017.07.75.
Abstract
摘要
相似文献
1
Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy.
J Thorac Dis. 2017 Aug;9(8):2308-2310. doi: 10.21037/jtd.2017.07.75.
2
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
N Engl J Med. 2017 May 18;376(20):1933-1942. doi: 10.1056/NEJMoa1609581.
3
No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
Expert Opin Pharmacother. 2017 Oct;18(14):1439-1442. doi: 10.1080/14656566.2017.1365838. Epub 2017 Aug 14.
4
ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.
JAMA Cardiol. 2018 May 1;3(5):401-408. doi: 10.1001/jamacardio.2018.0569.
5
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
JAMA. 2011 Nov 16;306(19):2099-109. doi: 10.1001/jama.2011.1649.
6
Evacetrapib: Another CETP Inhibitor for Dyslipidemia With No Clinical Benefit.
Cardiol Rev. 2017 Mar/Apr;25(2):43-52. doi: 10.1097/CRD.0000000000000137.
7
Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.
Atherosclerosis. 2017 Jun;261:12-18. doi: 10.1016/j.atherosclerosis.2017.04.008. Epub 2017 Apr 8.
8
Efficacy and Safety of Evacetrapib for Modifying Plasma Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Curr Pharm Des. 2016;22(5):595-608. doi: 10.2174/1381612822666151125000035.
9
Evacetrapib reduces preβ-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes.
Atherosclerosis. 2019 Jun;285:147-152. doi: 10.1016/j.atherosclerosis.2019.04.211. Epub 2019 Apr 14.
10
Efficacy and Safety of Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib Administered as Monotherapy in Japanese Patients With Primary Hypercholesterolemia.
Circ J. 2017 Oct 25;81(11):1686-1692. doi: 10.1253/circj.CJ-16-1325. Epub 2017 Jun 23.
引用本文的文献
1
Comparative Effectiveness of Cholesteryl Ester Transfer Protein (CETP) Inhibitors on Lipid Profiles in Adults With Hyperlipidemia: A Comprehensive Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials.
Clin Cardiol. 2025 Sep;48(9):e70204. doi: 10.1002/clc.70204.
2
Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?
Diseases. 2017 Sep 29;5(4):21. doi: 10.3390/diseases5040021.
本文引用的文献
1
ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity.
Sci Rep. 2017 May 24;7(1):2312. doi: 10.1038/s41598-017-02601-7.
2
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
N Engl J Med. 2017 May 18;376(20):1933-1942. doi: 10.1056/NEJMoa1609581.
3
Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.
Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1206-1212. doi: 10.1161/ATVBAHA.117.309007. Epub 2017 May 4.
4
Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.
Atherosclerosis. 2017 Jun;261:12-18. doi: 10.1016/j.atherosclerosis.2017.04.008. Epub 2017 Apr 8.
5
Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
Atherosclerosis. 2017 Feb;257:186-194. doi: 10.1016/j.atherosclerosis.2017.01.011. Epub 2017 Jan 16.
6
Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients.
J Clin Lipidol. 2016 May-Jun;10(3):519-527.e4. doi: 10.1016/j.jacl.2015.11.014. Epub 2015 Dec 18.
7
Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
Expert Rev Cardiovasc Ther. 2016 Aug;14(8):953-62. doi: 10.1080/14779072.2016.1189327. Epub 2016 May 28.
8
Plasma levels of apolipoprotein E and risk of ischemic heart disease in the general population.
Atherosclerosis. 2016 Mar;246:63-70. doi: 10.1016/j.atherosclerosis.2015.12.038. Epub 2015 Dec 29.
9
Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib.
J Am Coll Cardiol. 2015 Nov 17;66(20):2201-2210. doi: 10.1016/j.jacc.2015.09.013.
10
Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes.
J Pharmacol Exp Ther. 2015 Apr;353(1):27-34. doi: 10.1124/jpet.114.221002. Epub 2015 Jan 23.
Zotero 插件